HuGE Literature Finder
Records
1
-
30
[Detection and Diagnostic Values of JAK2, CALR, MPL Gene Mutations in 208 Cases of BCR/ABL1 Negative Chronic Myeloproliferative Diseases]. Zhongguo shi yan xue ye xue za zhi 2018 Aug 26 (4): 1122-1128. Li Zhen-Ling, Gao Li, Zhang Hui, Zhang Chun-Xia, Chen Yan-Rong, Huang Fan-Zhou, Gong Ming, Gao Ya-Yue, Tang Yin, Ma Yi-G |
Jak-2 mutation frequency in patients with thrombocytosis. Caspian journal of internal medicine 2018 9 (2): 189-193. Yokus Osman, Gedik Hab |
Prevalence of MPL (W515K/L) Mutations in Patients with Negative-JAK2 (V617F) Myeloproliferative Neoplasm in North-East of Iran. Iranian journal of pathology 2018 13 (4): 397-402. Shams Seyyede Fatemeh, Ayatollahi Hossein, Sadeghian Mohammad Hadi, Afzalaghaee Monavar, Shakeri Sepideh, Yazdandoust Ehsan, Sheikhi Maryam, Amini Nafiseh, Bakhshi Samane, Bahrami Afsa |
Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. American journal of clinical pathology 2017 May 147 (5): 444-452. Song Jinming, Hussaini Mohammad, Zhang Hailing, Shao Haipeng, Qin Dahui, Zhang Xiaohui, Ma Zhenjun, Hussnain Naqvi Syeda Mahrukh, Zhang Ling, Moscinski Lynn |
[Mutation of CALR Gene in Patients with Chronic Myeloproliferative Neoplasm and Its Clinical Significance]. Zhongguo shi yan xue ye xue za zhi 2017 Feb 25 (1): 151-156. Tang Qin, Zhang Xiu-Wen, Xia Lei, Jiang Nai- |
The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia. American journal of hematology 2017 Feb . Mudireddy Mythri, Barraco Daniela, Hanson Curtis A, Pardanani Animesh, Gangat Naseema, Tefferi Ayal |
[Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease]. Terapevticheskii arkhiv 2017 89 (7): 4-9. Melikyan A L, Subortseva I N, Sudarikov A B, Kovrigina A M, Gilyazitdinova E A, Kolosheinova T I, Abdullaev A O, Treglazova S |
Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia. The Journal of molecular diagnostics : JMD 2016 Nov . Usseglio Fabrice, Beaufils Nathalie, Calleja Anne, Raynaud Sophie, Gabert Je |
Thrombotic risk correlates with mutational status in true essential thrombocythemia. European journal of clinical investigation 2016 Jun . Bertozzi I, Peroni E, Coltro G, Bogoni G, Cosi E, Santarossa C, Fabris F, Randi M |
Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leukemia research 2016 Apr 46 18-25. Gugliotta Luigi, Iurlo Alessandra, Gugliotta Gabriele, Tieghi Alessia, Specchia Giorgina, Gaidano Gianluca, Scalzulli Potito R, Rumi Elisa, Dragani Alfredo, Martinelli Vincenzo, Santoro Cristina, Randi Maria Luigia, Tagariello Giuseppe, Candoni Anna, Cattaneo Daniele, Ricco Alessandra, Palmieri Raffaele, Liberati Marina A, Langella Maria, Rago Angela, Bergamaschi Micaela, Monari Paola, Miglio Rossella, Santoro Umberto, Cacciola Rossella, Rupoli Serena, Mastrullo Lucia, Musto Pellegrino, Mazzucconi Maria Gabriella, Vignetti Marco, Cortelezzi Agostino, Vianelli Nicola, Martino Bruno, Stefano Valerio De, Passamonti Francesco, Vannucchi Alessandro M, |
Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. American journal of hematology 2016 Feb . Patnaik Mrinal M, Lasho Terra L, Finke Christy M, Hanson Curtis A, King Rebecca L, Ketterling Rhett P, Gangat Naseema, Tefferi Ayal |
Determination of prognosis of Philadelphia chromosome-negative myeloproliferative neoplasms with a simple clinical examination: Retrospective analysis of 71 patients in a single institution. Molecular and clinical oncology 2016 Jan 4 (1): 51-57. Ito Shinichi, Tsutsumi Yutaka, Ohigashi Hiroyuki, Shiratori Souichi, Teshima Takano |
JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis. Journal of Korean medical science 2015 Jul 30 (7): 882-8. Kim Bo Hyun, Cho Young-Uk, Bae Mi-Hyun, Jang Seongsoo, Seo Eul-Ju, Chi Hyun-Sook, Choi Yunsuk, Kim Dae-Young, Lee Jung-Hee, Lee Je-Hwan, Lee Kyoo-Hyung, Park Young-Mi, Lee Jong-Keuk, Park Chan-Jeou |
Are all cases of paediatric essential thrombocythaemia really myeloproliferative neoplasms? Analysis of a large cohort. British journal of haematology 2015 May 169 (4): 584-9. Randi Maria L, Geranio Giulia, Bertozzi Irene, Micalizzi Concetta, Ramenghi Ugo, Tucci Fabio, Notarangelo Lucia D, Ladogana Saverio, Menna Giuseppe, Giordano Paola, Consarino Caterina, Farruggia Piero, Zanazzo Giulio A, Fiori Giovanni M, Burnelli Roberta, Russo Giovanna, Jankovich Momcilo, Peroni Edoardo, Duner Elena, Basso Giuseppe, Fabris Fabrizio, Putti Maria |
Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis. Molecular biology reports 2014 Oct 41 (10): 6737-42. Cetin Güven, Ozkan Tuba, Turgut Seda, Ali Cikrikcioglu M, Cem Ar M, Ayer Mesut, Unlu Ayhan, Celik Sevda Rabia, Sekin Yahya, Karatoprak Cuma |
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2014 Mar 123 (10): 1552-5. Rotunno Giada, Mannarelli Carmela, Guglielmelli Paola, Pacilli Annalisa, Pancrazzi Alessandro, Pieri Lisa, Fanelli Tiziana, Bosi Alberto, Vannucchi Alessandro M, |
The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Journal of hematology & oncology 2014 7 48. Wu Zhiyuan, Zhang Xinju, Xu Xiao, Chen Yuming, Hu Tingting, Kang Zhihua, Li Shibao, Wang Hua, Liu Weiwei, Ma Xiaochao, Guan Mi |
Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 2013 Sep 27 (9): 1826-31. Broséus J, Alpermann T, Wulfert M, Florensa Brichs L, Jeromin S, Lippert E, Rozman M, Lifermann F, Grossmann V, Haferlach T, Germing U, Luño E, Girodon F, Schnittger S, |
Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population. British journal of haematology 2013 Jan 160 (1): 70-9. Nielsen Camilla, Birgens Henrik S, Nordestgaard Børge G, Bojesen Stig |
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases. Haematologica 2012 Dec 97 (12): 1890-4. Schnittger Susanne, Bacher Ulrike, Alpermann Tamara, Reiter Andreas, Ulke Madlen, Dicker Frank, Eder Christiane, Kohlmann Alexander, Grossmann Vera, Kowarsch Andreas, Kern Wolfgang, Haferlach Claudia, Haferlach Torst |
Absence of JAK2V617F mutation in patients with beta-thalassemia major and thrombocytosis due to splenectomy. Molecular biology reports 2012 May 39 (5): 6101-5. Vlachaki E, Kalogeridis A, Neokleous N, Perifanis V, Klonizakis F, Ioannidou E, Klonizakis |
Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood 2012 Mar 119 (10): 2219-27. Giona Fiorina, Teofili Luciana, Moleti Maria Luisa, Martini Maurizio, Palumbo Giovanna, Amendola Angela, Mazzucconi Maria Gabriella, Testi Anna Maria, Pignoloni Patrizia, Orlando Sonia Maria, Capodimonti Sara, Nanni Mauro, Leone Giuseppe, Larocca Luigi Maria, Foà Rob |
Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis. Journal of the Formosan Medical Association = Taiwan yi zhi 2012 Jan 111 (1): 34-40. Ho Ching-Liang, Wu Yi-Ying, Hung Hsiu-Man, Chang Ping-Ying, Kao Wei-You, Chen Yeu-Chin, Chao Tsu- |
A study of JAK2 (V617F) gene mutation in patients with chronic myeloproliferative disorders. La Clinica terapeutica 2012 163 (2): 109-13. Hamidah N H, Farisah N R, Azlinda A B, Wong F L, Das S, Fadillah S A W, Ainoon |
Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica 2011 Oct 96 (10): 1462-9. Stein Brady L, Williams Donna M, O'Keefe Christine, Rogers Ophelia, Ingersoll Roxann G, Spivak Jerry L, Verma Amit, Maciejewski Jarek P, McDevitt Michael A, Moliterno Alison |
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 2011 Mar 117 (10): 2813-6. Passamonti Francesco, Elena Chiara, Schnittger Susanne, Skoda Radek C, Green Anthony R, Girodon François, Kiladjian Jean-Jacques, McMullin Mary Frances, Ruggeri Marco, Besses Carles, Vannucchi Alessandro M, Lippert Eric, Gisslinger Heinz, Rumi Elisa, Lehmann Thomas, Ortmann Christina A, Pietra Daniela, Pascutto Cristiana, Haferlach Torsten, Cazzola Mar |
Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients. Experimental hematology 2011 Jan 39 (1): 95-101. Stein Brady L, Williams Donna M, Rogers Ophelia, Isaacs Mary Ann, Spivak Jerry L, Moliterno Alison |
Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. British journal of haematology 2010 Apr 149 (2): 250-7. Boyd Elaine M, Bench Anthony J, Goday-Fernández Andrea, Anand Shubha, Vaghela Krishna J, Beer Phillip, Scott Mike A, Bareford David, Green Anthony R, Huntly Brian, Erber Wendy |
JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia. The Korean journal of hematology 2010 Mar 45 (1): 46-50. Jekarl Dong Wook, Han Sang Bong, Kim Myungshin, Lim Jihyang, Oh Eun-Jee, Kim Yonggoo, Kim Hee-Je, Min Woo-Sung, Han Kyung |
Acquired mutation of the tyrosine kinase JAK2V617F in Egyptian patients with myeloid disorders. Genetic testing and molecular biomarkers 0 15 (1-2): 17-21. Ayad Mona Wagdy, Nafea Dal |
- Page last reviewed:Oct 1, 2021
- Page last updated:Jul 06, 2022
- Content source: